A novel non-viral delivery method that enables efficient engineering of primary human T cells for ex vivo cell therapy applications

CRISPR-engineered T cells in patients with refractory cancer

Edward A. Stadtmauer, Joseph A. Fraietta, Megan M. Davis et al. · Science · 2020 · 1.4K citations · Full text

Life Sciences, Biotechnology, Immunology +17

Reprogramming human T cell function and specificity with non-viral genome targeting

Theodore L. Roth, Cristina Puig-Saus, Ruby Yu et al. · Nature · 2018 · 853 citations · Full text

Life Sciences, Biotechnology, Immunology +16

CD19 CAR T cell product and disease attributes predict leukemia remission durability

Olivia Finney, Hannah Brakke, Stephanie Rawlings-Rhea et al. · Journal of Clinical Investigation · 2019 · 350 citations · Full text

Life Sciences, Immunology, Oncology +17

Reducing <i>Ex Vivo</i> Culture Improves the Antileukemic Activity of Chimeric Antigen Receptor (CAR) T Cells

Saba Ghassemi, Selene Nuñez-Cruz, Roddy S. O’Connor et al. · Cancer Immunology Research · 2018 · 302 citations · Full text

Life Sciences, Immunology, Oncology +15

Cationic polymers for non-viral gene delivery to human T cells

Brynn R. Olden, Yilong Cheng, Jonathan L. Yu et al. · Journal of Controlled Release · 2018 · 192 citations · Full text

Pharmacy, Immunology, Pharmaceutics +16